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Abstract
Background: Streptococcus suis is an encapsulated Gram-positive bacterium and the leading cause of sepsis and
meningitis in young pigs, resulting in considerable economic losses in the porcine industry. S. suis is considered an
emerging zoonotic agent with increasing numbers of human cases over the last years. In the environment, both
avirulent and virulent strains occur in pigs, with no evidence for consistent adapatation of virulent strains to the human
host. Currently, there is an urgent need for a convenient, reliable and standardised animal model to rapidly assess S. suis
virulence. Wax moth (Galleria mellonella) larvae have successfully been used in human and animal infectious disease
studies. Here, we developed G. mellonella larvae as a model to assess virulence of S. suis strains.
Results: Fourteen isolates of S. suis belonging to different serotypes killed G. mellonella larvae in a dose-dependent
manner. Larvae infected with the virulent serotype 2 strain, S. suis S3881/S10, were rescued by antibiotic therapy.
Crucially, the observed virulence of the different serotypes and mutants was in agreement with virulence observed in
piglets (Sus scrofa) and the zebrafish larval infection model. Infection with heat-inactivated bacteria or bacteria-free
culture supernatants showed that in most cases live bacteria are needed to cause mortality in G. mellonella.
Conclusions: The G. mellonella model is simple, cost-efficient, and raises less ethical issues than experiments on
vertebrates and reduces infrastructure requirements. Furthermore, it allows experiments to be performed at the
host temperature (37 °C). The results reported here, indicate that the G. mellonella model may aid our
understanding of veterinary microbial pathogens such as the emerging zoonotic pathogen S. suis and generate
hypotheses for testing in the target animal host. Ultimately, this might lead to the timely introduction of new
effective remedies for infectious diseases. Last but not least, use of the G. mellonella infection model to study S.
suis virulence adheres to the principles of replacement, reduction and refinement (3Rs) and can potentially
reduce the number of vertebrates used for experimental infection studies.
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Background
Streptococcus suis is an emerging zoonotic Gram-
positive bacterial pathogen [1, 2] and the leading cause
of sepsis and meningitis in piglets. Infections with S. suis
have been reported worldwide throughout the pig pro-
duction industry and have led to considerable economic
losses [3, 4]. Recently, S. suis isolates causing more rapid
and severe infections in both humans and pigs have
been reported [5], raising concerns about the emergence
of more virulent strains [6–10].
The most common symptoms caused by virulent S.
suis in pigs and humans are meningitis, endocarditis and
streptococcal toxic shock-like syndrome [11–13]. In
spite of the importance of S. suis as a porcine pathogen
and zoonotic agent, relatively little is known about
epidemiology and virulence mechanisms leading to
carriage and invasive disease. Genetic analysis of virulence
and pathogenicity is not trivial as S. suis possesses multi-
factorial virulence factors [1]. The matter is further com-
plicated because natural populations are characterized by
high rates of recombination [14, 15], leading to many
different genotypes [4]. A generally accepted virulence
factor of S. suis is the capsular polysaccharide [16]. The
critical role of the capsular polysaccharide in virulence
and pathogenicity of S. suis has been demonstrated in
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multiple independent studies [17–19]. Of the 33 sero-
types of the capsular polysaccharide identified so far,
serotype 2 is the most frequently associated with inva-
sive disease [6, 20]. Other serotypes often associated
with porcine disease include serotype 1, 9, and 14 [21,
22]. S. suis colonises the upper respiratory tract of pigs
and the intestine [23, 24]. Healthy pigs carrying S. suis
are a source for S. suis transmission to the rest of the
pigs in the herd [23]. Currently, it is not possible to dis-
tinguish a virulent strain from a non-pathogenic strain
using molecular markers [1] highlighting the need for bet-
ter genomic markers of virulence and/or animal models
to rapidly assess the virulence of different S. suis isolates.
Pigs and mice have been successfully employed for S.
suis virulence studies [5, 25]. However, pigs and mice
have economical, logistic and ethical disadvantages over
non-mammalian infection models. Recently, the zebrafish
(Danio rerio) larval model has been validated for assessing
virulence of S. suis strains [26]. G. mellonella larvae have
been successfully utilised to study the virulence of other
important pathogens, including Streptococcus spp., and to
characterize existing and novel antibacterials [27–32]. G.
mellonella larvae are exempt from ethical legislation. The
larvae are cheap to purchase allowing experiments to be
performed with a large number of samples. Furthermore,
unlike other non-mammalian models, e.g. Caenorabditis
elegans, Drosophila melanogaster, or zebrafish larvae, G.
mellonella allows experiments to be performed at 37 °C,
the body temperature of the natural hosts. Last but not least,
the insect immune system exhibits both humoral and cellu-
lar components, and in some aspects the immune response is
similar to the innate immune response of mammals [33]. For
example, both insect hemocytes and mammalian neutrophils
engulf and kill pathogens, and both types of cell produce
superoxide, using similar p47 and p67 proteins [34]. Never-
theless, G. mellonella larvae are distantly related to pigs, and
it is important to establish their predictive value for virulence
in the natural host. A first step towards this goal is to com-
pare the virulence of a range of clinical and non-clinical S.
suis strains that differ in virulence in the natural host. Here,
we evaluated the use of G. mellonella larvae as an in vivo
model to assess virulence of S. suis isolates.
Methods
Bacteria and growth conditions
S. suis strains used in this study are listed in Table 1. S.
suis were stored at −80 °C in 20% (v/v) glycerol. S. suis
strains were cultured routinely in Mueller Hinton broth
(MHB) (Difco, USA) at 37 °C in the presence of 5% CO2
without shaking. For each strain studied, a calibration
curve was generated for absorbance measurements of
bacterial cultures at 600 nm (OD600) by plating aliquots
on MH agar (1% v/v) to calculate the bacterial colony
forming units per milliliter (CFU/ml) (data not shown).
G. mellonella larvae
G. mellonella larvae in their final instar stage were pur-
chased (UK Waxworms Ltd, Sheffield, UK), and stored
in the dark at 15 °C, and used within 14 days. Larvae
were separated by weight, and only larvae between 0.2
and 0.3 g were used for experiments. Unless otherwise
stated, all experiments in G. mellonella were performed
using 15 larvae per group and in most cases repeated
using larvae from a different batch to give n = 30. Larvae
were injected with 20 μL of bacterial suspension, anti-
biotic solution, or phosphate buffered saline (PBS) in the
left posterior proleg using Terumo Myjector 29G insulin
syringes (VWR International). The syringes were changed
between treatments with different strains. Two negative
control groups were included in every experiment; one
group was not injected to control for background larval
mortality (no manipulation control) and the other group
(uninfected control) was injected with PBS to control for
the possible effect of physical trauma on mortality. Larvae
were stored in Petri dishes in the dark at 37 °C with 5%
CO2 for up to 144 h post-infection (p.i.) and inspected
every 24 h for survival; larvae were considered dead if they
did not move after shaking of the petri dish.
Virulence of S. suis in G. mellonella
Infection of G. mellonalla larvae with S. suis strains was
performed as described previously for other pathogens
[27, 28]. Larvae were infected in the left posterior proleg
with 20 μl inocula of different S. suis strains containing
between 1 × 105 CFU/mL to 1 × 108 CFU/mL. Survival
of larvae was recorded at 24 h intervals for 144 h p.i.. A
heat-killed S. suis inoculum of > 1 × 108 CFU/ml incu-
bated at 99 °C for 30 min was used as a negative control
in the infection experiments. In some experiments S.
suis culture supernatants were prepared by centrifuga-
tion of overnight cultures (i.e. > 1 × 108 CFU/ml) at 11
000 g for 30 min and injected into the posterior proleg
of groups of larvae as described above. The absence of
viable S. suis in culture supernatants and heat inacti-
vated cultures was confirmed by plating on MH agar
and incubation at 37 °C for 24 h.
Antibiotic treatment
Antibiotic stock solutions were prepared in 1× PBS. For
studies of antibiotic efficacy, an inoculum of 1 × 107 CFU/
mL of S. suis 3881/S10 was used. A single treatment with
antibiotics was administered 2 h p.i. via the posterior
proleg.
Statistical analysis
Survival data were plotted using the Kaplan–Meier method
and comparisons between groups were made using the
log-rank test using GraphPad Prism v 5.03. In all compari-
sons with the negative control, it was the uninfected control
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(rather than the un-manipulated control) that was used. In
all tests, P ≤ 0.05 was considered significant. The lethal dose
leading to 50% mortality (LD50) at different time points
was determined by plotting the percentage of surviving
larvae following infection with different inocula, and
non-linear curve fitting using GraphPad Prism v 5.03.
Results
Galleria mellonella larvae are sensitive to infection by
Streptococcus suis
The virulence of S. suis isolates (Table 1) that had been
assessed for virulence in a piglet infection model [35]
was assessed in G. mellonella larvae by inoculation with
20 μL of suspensions containing 1 × 105 to 1 × 108 CFU/ml
and incubation at 37 °C. Notably, isolates reported as viru-
lent in pigs (6388, 6555/NCTC 428, P1/7, 3881/S10, 7997)
[35] and in a zebrafish larval model (3881/S10, 6555/NCTC
428) [26] showed dose-dependent virulence in G. mello-
nella larvae (Figs. 1 and 2, Table 1). Isolates reported as
weakly virulent or avirulent in piglets (T15, S735R2)
showed attenuated virulence in G. mellonella larvae
compared to the virulent strains, e.g. 3881/S10 (Figs. 1
and 2, Table 1). One generally accepted virulence factor
of S. suis is the capsular polysaccharide, and its critical
role in virulence and pathogenicity has been demon-
strated in multiple independent studies [17, 18, 26]. A
mutant lacking the capsular polysaccharide, the serotype 2
mutant cpsΔEF [17], showed more than 20 times attenu-
ated virulence to G. mellonella larvae compared to the wild
type, 3881/S10 (Figs. 1 and 2, Additional file 1: Figure S1,
and Table S1). After 24 h p.i. 5 × 106 CFU/ml of the wt
3881/S10 lead to 50% mortality, whereas more than 1×108
CFU/ml of the mutant lacking the capsular polysacharyde,
cpsΔEF, are needed for 50% mortality 24 h p.i. These results
confirm the applicability of the G. mellonella larvae infec-
tion model to study S. suis virulence factors. Furthermore,
we studied isolates for which virulence data in piglet infec-
tion models has not been reported. G. mellonella larvae
were infected with isolates from different clinical sources
(central nervous system, bacteraemia, speticemia, joins, and
tonsils, Table 1). Six of the studied isolates (15965,
5213, 8039, 7709, 7998, 5128/22083) showed dose-
dependent virulence (Figs. 1 and 2). The serotype 9
isolates 5128/22083 and 7709 were among the most
virulent isolates tested in G. mellonella larvae (Figs. 1
and 2 and Additional file 1: Figure S1, and Table 1 and
Additional file 1: Table S1). Another serotype 9 isolate,
7998, showed virulence comparable to the virulence of
the serotype 2 isolates 3881/S10 and P1/7. Isolates
5213 (serotype 4) and 8039 (serotype 7) showed weaker
virulence, comparable to the non-capsulated serotype 2
mutant cpsΔEF (Figs. 1 and 2 and Additional file 1: Figure
S1 and Table 1 and Additional file 1: Table S1). The sero-
type 3 isolate 15965 showed virulence comparable to the
virulence of P1/7 (serotype 2). Isolates C132 and 8186
(both serotype 9) were weakly virulent (Figs. 1 and 2 and
Additional file 1: Figure S1, and Table 1 and Additional
file 1: Table S1).
Melanisation in G. mellonella is thought to be a key
part of the defence against a range of pathogens [29].
Table 1 Virulence of bacterial strains used in this study. HV stands for highly virulent, V stands for virulent, WV stands for weakly
virulent, and AV stands for avirulent. The virulence in pigs is described in [35] and the scale of virulence in pig infection model is as
described in [35]. Strains leading to more than 50% mortality of G. mellonella larvae post-infection with 107 CFU/ml were considered viru-
lent, and strains leading to less than 50% mortality of G. mellonella larvae were considered weakly virulent
Strain Serotype Virulence in pigs [35] Virulence in G. mellonella Clinical source Reference/source
6388 1 HV V Organs Laboratory collection [45]
6555/NCTC 428 1 V WV
T15 2 AV WV Tonsil Laboratory collection [46]
S735R2 2 WV WV Unknown Laboratory collection [35]
P1/7 2 V V Unknown Laboratory collection [35]
3881/S10 2 V V [47]
(J28) S10 cpsΔEF 2 AV WV [17]
15965 3 ND V
5213 4 ND V
8039 7 ND V CNS Laboratory collection [40]
7709 9 ND V Bacteraemia Laboratory collection [40]
C132 9 ND WV Brain/septicemia Laboratory collection [40]
7998 9 ND V Joint Laboratory collection [40]
8186 9 ND WV Tonsil Laboratory collection [40]
5128/22083 9 ND V
V virulent, HV highly virulent, WV weakly virulent, AV avirulent, ND not determined
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Melanin is deposited around microbes within the
hemolymph where it is believed to facilitate pathogen
killing [29]. Over the course of S. suis infection, G.
mellonella larvae showed obvious signs of melanisation
similar to melanisation induced by infection with other
pathogens (Additional file 1: Figure S2).
The culture supernatants or heat-treated extracts of specific
strains induced mortality in G. mellonella larvae
To examine the effect of bacteria-free culture superna-
tants on larval survival, 20 μl was injected through the
left posterior proleg. For most strains the supernatant of
an overnight culture (more than 1 × 108 CFU/ml) did not
Fig. 1 Dose dependent virulence of different S. suis strains belonging to serotype 1 to 3 (Table 1). Survival data were plotted using the Kaplan–Meier
method using GraphPad Prism v 5.03. The dotted lines represent the standard error. The observed virulence is in agreement with virulence observed
in a piglet infection model (Table 1)
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significantly affect larval survival (Additional file 1: Figure
S3) indicating that the exotoxin suilysin or endotoxins re-
leased into the growth medium were not causing mor-
tality. The exception was strain 7709 for which the
bacteria-free supernatant showed significantly increased
mortality compared to the PBS control (p value 0.0085)
indicating toxicity due to secreted factor(s). The heat inacti-
vated inoculum (containing both the heat-treated cells and
heat-treated supernatant) of 7709 did not lead to a signifi-
cantly different effect than the PBS control. These indicate
that the factor(s) in the 7709 supernatant causing mortality
of the G. mellonella larvae is temperature sensitive.
Fig. 2 Dose dependent virulence of different S. suis strains belonging to serotype 4, 7 and 9 (Table 1). Survival data were plotted using the
Kaplan–Meier method using GraphPad Prism v 5.03. The dotted lines represent the standard error. The observed virulence is in agreement with
virulence observed in a piglet infection model (Table 1)
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The heat-inactivated inoculum of 8039 and 5213 signifi-
cantly increased larval mortality compared to the PBS
injected control group (p values of 0.0481 and < 0.0001,
respectively). The virulence of the live bacteria of 8039
and 5213 is comparable to the non-capsulated serotype 2
mutant cpsΔEF and to the weakly virulent serotype 2 iso-
late S735 (Figs. 1 and 2 and Additional file 1: Figure S1,
and Table 1 and Additional file 1: Table S1).
Antibiotic treatment rescues larvae infected with S. suis
3881/S10
G. mellenella larvae have been used to study antibiotic
treatment for different bacterial and fungal infections
[27, 35, 36]. To assess the utility of G. mellonella larvae
to study antibacterial therapies against S. suis, we con-
firmed that antibiotic therapy could rescue larvae from
S. suis infection. Larvae were infected with 1 × 107 CFU
of the S. suis strain 3881/S10, a well characterised sero-
type 2 strain previously shown to be virulent in pigs and
used in our previous research [37, 38, 39]. At 2 h p.i. the
larvae were treated with doxycycline, amoxicillin and
ampicillin (25 mg/kg). Additional control groups were
assessed for the toxicity of the antibiotic treatment (data
not shown). Treatment with 25 mg/kg of each of the an-
tibiotics rescued the larvae, and 144 h p.i. there was
100% survival rate of the larvae treated with the three
different antibiotics, compared to infected larvae that
were not treated with antibiotics (data not shown).
Deletion of the two-component system CiaRH reduced S.
suis virulence in G. mellonella larvae
The two component system (TCS) CiaRH contributes to
the virulence of S. suis serotype 2 [40]. Deletion of the
ciaRH operon results in a lower survival rate in a bac-
tericidal assay compared to the wild-type. Furthermore,
the mutant showed reduced virulence in mice and pigs
in vivo, and in a zebrafish larval model of S. suis infec-
tion [26]. In order to assess whether reduced virulence
of S. suis strain S10 ΔciaRH would also be observed in
G. mellonella larvae, we compared the survival of larvae
infected with 1 × 107 CFU/ml of the mutant strain S10
ΔciaRH or the wild type 3881/S10. Infection of larvae by
the ΔciaRH strain resulted in a significantly higher
survival rate compared to infection with the 3881/S10
wild-type strain, (p < 0.0001) (Fig. 3). Thus, the observed
results in G. mellonella larvae are in agreement with re-
sults obtained with the same two isolates in mouse and
pig infection studies, and in zebrafish larval infection
model. Taken together these results indicate that G. mel-
lonella larvae can be used to assess virulence of porcine
S. suis strains reproducibly and in a biologically mean-
ingful way.
S. suis suilysin mutant shows reduced virulence in G.
mellonella larvae
S. suis produces a secreted membrane damaging toxin,
suilysin suggested which is to contribute to virulence
[41]. An allelic replacement insertion mutant of S. suis
strain P1/7 lacking functional sly, (Δsly), is not haemo-
lytic and unlike the wild type P1/7 does not efficiently
kill J774.2 cellsin vitro [40]. Furthermore, the deletion of
suilysin mutation prevented S. suis from killing mice via
the intraperitoneal route of infection [40]. In pig infec-
tion models, the mean survival times of the wild type P1/
7 and the suilysin mutant Δsly were not significantly dif-
ferent [42]. In G. mellonella infection with 107 CFU/ml of
the Δsly mutant showed slightly more than 2 times
Fig. 3 a Survival rate of G. mellonela larvae injected with 105 – 107 CFU/ml of the S10 ΔciaRH mutant. b Comparison of the survival rate of larvae
infected with 107 of S10 ΔciaRH mutant and the wild-type 3881/S10 strain. Survival data were plotted using the Kaplan–Meier method and
comparisons between groups were made using the log-rank test using GraphPad Prism v 5.03. The dotted lines represent standard error
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attenuated virulence 24 p.i. compared to the wild type
P1/7 (Fig. 4). However, 48 to 144 h p.i. the virulence of the
Δsly mutant was attenuated more than 1.5 fold compared
to the wild-type strain P1/7. The attenuated virulence of
the Δsly mutant in G. mellonella larvae compared to the
wild-type stain P/7 is in agreement with the effects ob-
served in J774.2 cells in vitro and in the interperitoneal
mice infection model.
Discussion
The use of insect larvae for virulence testing of patho-
gens is not regulated by legislation and represents an al-
ternative to experimental infection of rodents or pigs.
Alternative infection models are important in order to
comply with the efforts to reduce, refine, and replace
animal experiments (the 3Rs). G. mellonella larvae have
been used as infection models for other important path-
ogens [29] and to study the efficacy of antibacterial and
antifungal therapies [28, 43, 38] due to the general simi-
larities between the wax worm innate immune system
and the innate immune response of higher organisms
[33]. As an infection model G. mellonella offers a number
of technical advantages over mammalian infection models
(e.g. high-throughput, ease of handling, simple housing
requirements, the possibility to purchase a large number
of larvae at a relatively low price, no legal or ethical issues
etc.). Importantly, experiments with G. mellonella larvae
unlike experiments with other non-mammalian models
(e.g. zebrafish larvae, C. elegans, or D. melanogaster) can
be performed at the body temperature of the mamma-
lian natural host, 37 °C. The immune system of insects,
including G. mellonella larvae, is very similar to the in-
nate immune response of mammals [33]. Therefore, re-
sults obtained using insects can serve as a starting point
to study pathogenesis and generate hypotheses to be fur-
ther tested in vertebrate models.
The present study aimed to validate G. mellonella larvae
as an alternative model to investigate the virulence of S.
suis. S. suis is an important zoonotic pathogen and
significant cause of meningitis and sepsis in pigs and
humans [6]. Clinical isolates of S. suis were shown to
kill G. mellonella larvae in a dose-dependent manner. Fur-
thermore, similar to infection with other pathogens, infec-
tion of G. mellonella larvae with virulent S. suis strains
triggered melanisation (Additional file 1: Figure S2). Mela-
nisaiton is part of the immune response in G. mellonella
considered a key step of the defense against a range of path-
ogens [29]. Melanin is deposited around microbes within
the haemolymph and is thought to facilitate pathogen kill-
ing. The strains with greater reported virulence in pigs were
also more virulent in G. mellonella supporting the predict-
ive value of the G. mellonella infection model. The correl-
ation in virulence of S. suis isolates in pigs and G.
mellonella was demonstrated using published virulence
data, i.e. no pigs were required for the experiments re-
ported here [35]. Additionally, we report on the viru-
lence of several S. suis strains that have not been
studied in pigs or rodent infection models. Live strains
of S. suis were required to significantly increase larval
mortality, the exception being strains 8039 and 5213
which still increased larval mortality when heat-killed
prior to injection at the highest dose. Nevertheless, the ef-
fect of larval survival infection with 8039 or 5213 is com-
parable to the effect of the weakly virulent serotype
2 S735 or the non-capsulated serotype 2 mutant cpsΔEF.
The bacteria-free culture supernatants of S. suis did
not induce significant death of larvae compared to the
control except in the case of the serotype 9 strain 7709,
Fig. 4 a Survival rate of G. mellonela larvae injected with 106 – 108 CFU/ml of the P1/7 Δsly mutant. b Comparison of the survival rate of larvae
infected with 107 of P1/7 Δsly mutant and the wild-type P1/7. Survival data were plotted using the Kaplan–Meier method and comparisons between
groups were made using the log-rank test using GraphPad Prism v 5.03
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which was among the most virulent strains tested in the
Galleria infection model (Additional file 1: Figure S1, and
Table S1). This might be due to higher expression of suily-
sin, the pore-forming toxin produced by most pathogenic
strains of S. suis, which is carbon catabolite repressed by
glucose when grown in vitro [44].
Conclusion
The use of invertebrate hosts such as G. mellonella, D.
melanogaster and C. elegans to study microbial patho-
genesis and host responses have contributed substan-
tially to biomedical research over the last decades. In
this study, we describe the utility of G. mellonella larvae
to study the virulence of the zoonotic pathogen S. suis.
Relatively little is known about the pathogenic mecha-
nisms of S. suis. Therefore, the infection model reported
here serves as a useful starting point for assessing the
strain virulence or the impact of genetic mutations on
virulence of S. suis. Interestingly, a good correlation
between the pathogenicity of S. suis in G. mellonella
and the virulence observed in pigs and humans, and in
other infection models such as zebrafish larval infection
model and mice infection model was observed. Further-
more, the infection model described here also has the po-
tential to be used to evaluate novel therapies for in vivo
activity against S. suis and help prioritise candidates for
testing in mammalian models.
Additional file
Additional file 1: Figure S1. LD50s of tested strains. Figure S2.
Infection with S. suis triggers melanisation in G. mellonella larvae. Figure
S3. Effect of cell-free supernatant and heat-inactivated inocula on G. mel-
lonella larvae survivial. Table S1. LD50s of tested strains. (DOC 2250 kb).
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